Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon

Digestive Diseases and Sciences

Volumn 44, Issue 5, 1999, Pages 1013-1019

  Almasio, Piero L ^a   Di Marco, Vito ^b   Bonura, Celestino ^b   Fuschi, Patrizia ^b   Cammà, Calogero ^b   Lo Iacono, Oreste ^b   Artini, Marco ^b   Natoli, Clara ^b   Di Stefano, Rosa ^b   Levrero, Massimo ^b   Craxi, Antonio ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b NONE

Author keywords

Chronic hepatitis; Hepatitis C virus; Hepatitis C virus genotypes; Interferon; Relapse

Indexed keywords

ALPHA2B INTERFERON;

ADULT; AGE; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RETREATMENT;

ADULT; ANTIVIRAL AGENTS; FEMALE; GLYCOPROTEINS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNORADIOMETRIC ASSAY; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RECURRENCE; RNA, VIRAL; ROC CURVE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0032942740     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026625001168     Document Type: Article

References (30)

1. Chemello L, Cavalletto L, Casarin C, Bonetti P, Bernardinello E, Pontisso P, Donada C, Belussi F, Martinell S, Alberti A: Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group. Ann Intern Med 124:1058-1060, 1996
2. Tinè F, Magrin S, Craxi A, Pagliaro L: Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol 13:192-199, 1991
3. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski P: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 24:778-789, 1996
4. Pagliaro L, Craxì A, Cammà C, Tinè F, Di Marco V, Lo Iacono O, Almasio P: Interferon-alpha for chronic hepatitis C: An analysis of pretreatment clinical predictors of response. Hepatology 19:820-828, 1994
5. Di Marco V, Lo Iacono O, Cammà C, Almasio PL, Vaccaro A, Fuschi P, Giunta M, Fabiano C, Pagliaro L, Craxì A: A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C. J Med Virol 51:17-24, 1997
6. Chemello L, Alberti A, Rose K and Simmonds P: Hepatitis C serotype and response to interferon therapy. N Engl J Med 330:143, 1994
7. Yamada G, Takatani M, Kishi F, Takahashi M, Doi T, Tsuji T, Schin S, Tanno M, Urdea MS, Kolberg JA: Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 22:1351-1354, 1995
8. Magrin S, Craxi A, Fabiano C, Marino L, Fiorentino G, Lo Iacono O, Volpes R, Di Marco V, Almasio P, Vaccaro A, Urdea MS, Wilber JC, Bonura C, Gianguzza F, Capursi V, Filiberti S, Stuyver L, Pagliaro L: HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (southern Italy). J Hepatol 25:583-590, 1996
9. Niederau C, Heintges T, Häussinger D: Treatment of chronic hepatitis C with α-interferon: An analysis of the literature. Hepatogastroenterology 43:1544-5615, 1996
10. Ballardini G, Groff P, Pontisso P, Giostra F, Francesconi R, Lenzi M, Zauli D, Alberti A, Bianchi, FB: Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A,B,C, and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C. J Clin Invest 95:2067-2075, 1995
11. Artini M, Natoli C, Tinari N, Costanzo A, Marinelli R, Balsano C, Porcari P, Angelucci D, D'Egidio M, Levrero M, Iacobelli S: Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to α-interferon therapy in chronic hepatitis patients. J Hepatol 25:212-217, 1996
12. Weiland O, Zang YY, Widel A: Serum HCV RNA levels in patients with chronic hepatitis C given a second course of interferon alpha-2b treatment after relapse following initial treatment. Scand J Infect Dis 25:25-30, 1993
13. Gerken G, Teuber G, Gorgen B, Meyer zum Buschenfelde KH: Interferon-alpha retreatment in chronic hepatitis C. J Hepatol 22(suppl 1):118-121, 1995
14. Hoefs JC: Retreatment followed by long term maintenance therapy of HCV patients with prior complete response to interferon followed by relapse. Hepatology 22:117, 1995 (abstract)
15. Picciotto A, Sinelli N, Brizzolara R, Campo N, Lapertosa G, Celle G: Long-term interferon alfa-2b retreatment of relapsing patients with chronic hepatitis C. J Hepatol 26:447-448, 1997
16. Payen JL, Izopet J, Galindo-Migeol V, Lauwers-Cances V, Zarski JP, Seigneurin JM, Dussaix E, Voigt JJ, Selves, J, Barange K, Puel J, Pascal JP, and Grp Etud Traitement Virus Hepatite C, Better efficacy of a 12-month interferon α-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: A multicenter, controlled, randomized trial. Hepatology 28:1680-1686, 1998
17. Le X, Zhou X, Dai X: Evaluation of interferon-alpha-2b for the treatment of relapsed hepatitis C. Hepatology 24:536, 1996 (abstract)
18. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heverswyn H, Maertens G: Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 74:1093-1102, 1993
19. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT, Chan SW, Chayama K, Chen DS, Choo QL, Colombo M, Cuypers HTM, Date T, Dusheiko GM, Esteban JI, Fay O, Hadziyannis SJ, Han J, Hatzakis A, Holmes EC, Hotta H, Houghton M, Irvine B, Kohara M, Kolberg JA, Kuo G, Lau JYN, Lelie PN, Maertens G, McOmish F, Miyamura T, Mizokami M, Nomoto A, Prince AM, Reesink HW, Rice C, Roggendorf M, Schalm SW, Shikata T, Shimotohno K, Stuyver L, Trépo C, Weiner A, Yap PL, Urdea MS: A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 19:1321-1324, 1994
20. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ: Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 19:1513-1520, 1994
21. Natoli C, Tinari N, D'Egidio M, Iacobelli S: The 90K antigen, a novel serologic marker of immune activation in HIV infection, Immunol Infect Dis 4:207-210, 1994
22. Schoonjans F, Zalata A, Depuydt CE, Comhaire FH: MedCale: A new computer program for medical statistics. Comp Methods Progr Biomed 48:257-262, 1995
23. Davis GL, Balart LA, Schiff ER, Bodenheimer HC, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, VanThiel D, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A, Hepatitis International Therapy Group: Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 321:1501-1506, 1989
24. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trépo C, Couzigou P, Payen JL, Sajus M, Costa JM, Vidaud M, Chaput JC, Multicenter Study Group: A comparison of three interferon alfa-2b regimens for long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 332:1457-1462, 1995
25. Craxì A, Di Marco V, Lo Iacono O, Almasio P, Bruno R, Cammà C, Volpes R, Pagliaro L: Transfusion-associated chronic hepatitis C: Alpha-nl interferon for 6 vs 12 months. J Hepatol 24:539-546, 1996
26. Alberti A, Chemello L, Noventa F, Cavalletto L, De Salvo G: Therapy of hepatitis C: Re-treatment with alpha interferon. Hepatology 26(suppl 1):137S-142S, 1997
27. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, Asti M, Rossi S, Larghi A, Cerino A, Podda M, Mondelli M: Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study. Hepatology 25:754-758, 1997
28. Schvarcz R, Yun ZB, Sönnerborg A, Weiland O: Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Virol 46:43-47, 1995
29. Brillanti S, Miglioli M, Barbara L: Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. J Hepatol 23(suppl 2):13-15, 1995
30. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, Cavalletto L, Schvarcz R, Ideo G, Alberti A: Ribavirin enhances the efficacy but not the adverse effect of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 26:961-966, 1997